trans-Doxercalciferol
Based on 1 Customer Validation
trans-Doxercalciferol is an isomer of Doxercalciferol (HY-32348). Doxercalciferol is a vitamin D receptor agonist. Doxercalciferol reduces proteinuria, podocyte injury, mesangial expansion, extracellular matrix accumulation, macrophage infiltration, oxidative stress, proinflammatory cytokines, profibrotic growth factors, renal neutral lipid accumulation, albuminuria and glomerulosclerosis. Doxercalciferol alleviates high-salt diet-induced myocardial hypertrophy. trans-Doxercalciferol is used for the research of diet-induced obesity-related nephropathy, diabetic nephropathy, myocardial hypertrophy, cardiac dysfunction and secondary hyperparathyroidism.
For research use only. We do not sell to patients.
- Purity: 98.20%
- CAS No.: 74007-20-8
- Formula: C28H44O2
- Molecular Weight:412.65
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Transcription Factor-Targeted Library
HY-L090
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Vitamin Compound Library
HY-L197
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
Doxercalciferol (150-250 ng; intraperitoneal injection; three times per week; for 6 consecutive weeks) alleviates high-salt diet-induced myocardial hypertrophy, improves cardiac dysfunction, reduces the levels of hypertrophy biomarkers, and inhibits PKCα activation in male DSS rats, without causing significant changes in serum Ca2+ levels[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dahl salt sensitive (DSS) (male, 6 weeks of age, cardiac hypertrophy induced via 6-week high-salt (6% NaCl) diet)[3]
-
Dosage:150 ng; 250 ng
-
Administration:i.p.; 3 times weekly; 6 weeks
-
Result:Reduced heart weight/body weight ratio by 11%.
Reduced lung weight/body weight ratio by 29%.
Reduced diastolic left ventricle posterior wall thickness by 13%.
Improved fractional shortening by 17%.
Attenuated increased left ventricular mass.
Significantly reduced serum brain natriuretic peptide (BNP) levels.
Reduced left ventricular tissue atrial natriuretic factor (ANF) mRNA levels.
Reduced cardiomyocyte cross-sectional diameter by 22%.
Blocked high-salt diet-induced increases in cardiac protein kinase C-α (PKCα) protein level, membrane translocation of PKCα, and phosphorylated PKCα expression.
Did not cause significant changes in serum calcium levels (150 ng and 250 ng doses).
Had no significant effect on organ weights or serum calcium levels in normal diet-fed rats (150 ng dose).
Chemical Information
-
CAS No. 74007-20-8
-
Appearance Solid
-
Molecular Weight 412.65
-
Formula C28H44O2
-
Color White to off-white
-
SMILES
C=C([C@H](C[C@H](O)C/1)O)C1=C\C=C2[C@@]3([H])[C@@](CCC\2)(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 50 mg/mL (121.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011;300(3):F801-F810. [Content Brief]
[2]. Zhang Y, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009 Sep;297(3):F791-801. [Content Brief]
[3]. Choi JH, et al. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Card Fail. 2011;17(12):1051-1058. [Content Brief]
[4]. Kubodera N, et al. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules. 2009;14(10):3869-3880. Published 2009 Sep 29. [Content Brief]
[5]. Wesseling-Perry K, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79(1):112-119. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4234 mL | 12.1168 mL | 24.2336 mL | 60.5840 mL |
| 5 mM | 0.4847 mL | 2.4234 mL | 4.8467 mL | 12.1168 mL | |
| 10 mM | 0.2423 mL | 1.2117 mL | 2.4234 mL | 6.0584 mL | |
| 15 mM | 0.1616 mL | 0.8078 mL | 1.6156 mL | 4.0389 mL | |
| 20 mM | 0.1212 mL | 0.6058 mL | 1.2117 mL | 3.0292 mL | |
| 25 mM | 0.0969 mL | 0.4847 mL | 0.9693 mL | 2.4234 mL | |
| 30 mM | 0.0808 mL | 0.4039 mL | 0.8078 mL | 2.0195 mL | |
| 40 mM | 0.0606 mL | 0.3029 mL | 0.6058 mL | 1.5146 mL | |
| 50 mM | 0.0485 mL | 0.2423 mL | 0.4847 mL | 1.2117 mL | |
| 60 mM | 0.0404 mL | 0.2019 mL | 0.4039 mL | 1.0097 mL | |
| 80 mM | 0.0303 mL | 0.1515 mL | 0.3029 mL | 0.7573 mL | |
| 100 mM | 0.0242 mL | 0.1212 mL | 0.2423 mL | 0.6058 mL |
trans-Doxercalciferol Related Classifications
Cat. No.: HY-75992
Powered by Bioz
- trans-Doxercalciferol
- 74007-20-8
- Drug Isomer
- renin
- protein kinase C-α
- farnesoid X receptor
- mineralocorticoid receptor
- vitamin D receptor
- angiotensin II type 1 receptor
- angiotensinogen
- sterol regulatory element binding protein 2
- sterol regulatory element binding protein 1
- parathyroid hormone
- Inhibitor
- inhibitor
- inhibit